Equities research analysts expect Oncolytics Biotech Inc. (NASDAQ:ONCY) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Oncolytics Biotech’s earnings. Oncolytics Biotech posted earnings of ($0.12) per share in the same quarter last year, which would indicate a negative year over year growth rate of 25%. The business is expected to issue its next earnings results on Wednesday, November 10th.
On average, analysts expect that Oncolytics Biotech will report full year earnings of ($0.39) per share for the current fiscal year, with EPS estimates ranging from ($0.48) to ($0.29). For the next financial year, analysts forecast that the business will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.66) to ($0.31). Zacks’ EPS averages are an average based on a survey of research analysts that follow Oncolytics Biotech.
ONCY has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Oncolytics Biotech in a research report on Monday, August 16th. Zacks Investment Research cut Oncolytics Biotech from a “buy” rating to a “hold” rating in a report on Friday, September 10th.
Shares of ONCY opened at $2.07 on Friday. Oncolytics Biotech has a fifty-two week low of $1.56 and a fifty-two week high of $4.83. The company has a market capitalization of $113.77 million, a PE ratio of -4.22 and a beta of 2.72. The stock has a fifty day moving average of $2.28 and a two-hundred day moving average of $2.81.
About Oncolytics Biotech
Oncolytics Biotech, Inc engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
Read More: What is a management fee?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.